Find Clinical Trials

← Back
November 17, 2025 in Lung

A082304-S2402: Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer – PROSPECT LUNG (NCT06632327)

Read More
October 20, 2025 in Lung

S2409, PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC) (NCT# 06769126)

Read More
October 1, 2025 in Lung

S2414: A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT) (NCT06498635)

Read More
October 1, 2025 in Lung

BR.38: Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer – A Randomized Phase III Trial (NCT #06686771)

Read More
August 21, 2025 in Lung

BE6A Lung-02/ SigVie-003 (C5751003)

AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS…
Read More
June 23, 2025 in Lung

S1800E: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Read More
January 23, 2025 in Lung

PrE1702

Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients
Read More
June 17, 2024 in Lung

EA5221

Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Read More
June 26, 2023 in Lung

S1900G

A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Read More
September 14, 2022 in Lung

LungMAP

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Read More
September 14, 2022 in Lung

EA5162

EA5162: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR
Read More
August 3, 2022 in Lung

A092001

A092001: Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma
Read More
July 1, 2022 in Lung

LU007

LU007: RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial (NCT # NCT04402788)
Read More
June 30, 2022 in Lung

EA5182

EA5182: Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer (NCT04181060)
Read More
June 30, 2022 in Lung

CC009

CC009: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung Cancer
Read More
June 30, 2022 in Lung

A082002

A082002: A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1-Negative, Advanced Non-small Cell Lung Cancer (NCT04929041)
Read More
June 30, 2022 in Lung

A081801

A081801 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
Read More